$171 Million is the total value of Sio Capital Management, LLC's 43 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 60.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PHG | Sell | KONINKLIJKE PHILIPS NVny reg sh new | $6,404,000 | -53.2% | 209,502 | -54.7% | 3.74% | -60.4% |
| TRHC | Sell | TABULA RASA HEALTHCARE INC | $5,813,000 | -20.4% | 388,054 | -23.9% | 3.39% | -32.6% |
| CAH | Sell | CARDINAL HEALTH INC | $4,958,000 | -52.4% | 68,885 | -48.6% | 2.89% | -59.7% |
| AMGN | Sell | AMGEN INCcall | $2,924,000 | -80.8% | 20,000 | -78.1% | 1.71% | -83.8% |
| PRGO | Sell | PERRIGO COMPANY PLC | $2,441,000 | -32.1% | 29,329 | -24.7% | 1.42% | -42.6% |
| CCXI | Sell | CHEMOCENTRYX INC | $2,407,000 | -35.1% | 325,250 | -47.0% | 1.40% | -45.1% |
| SRPT | Sell | SAREPTA THERAPEUTICS INCput | $960,000 | -81.9% | 35,000 | -59.5% | 0.56% | -84.7% |
| FWP | Sell | FORWARD PHARMA A/Ssponsored adr | $769,000 | -56.9% | 51,246 | -39.8% | 0.45% | -63.6% |
| PFNX | Exit | PFENEX INC | $0 | – | -64,556 | -100.0% | -0.40% | – |
| VKTX | Exit | VIKING THERAPEUTICS INC | $0 | – | -849,905 | -100.0% | -0.82% | – |
| AFAM | Exit | ALMOST FAMILY INC | $0 | – | -36,479 | -100.0% | -0.92% | – |
| CHRS | Exit | COHERUS BIOSCIENCES INC | $0 | – | -73,053 | -100.0% | -1.35% | – |
| ACETQ | Exit | ACETO CORP | $0 | – | -115,781 | -100.0% | -1.52% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -112,497 | -100.0% | -1.56% | – |
| ANTH | Exit | ANTHERA PHARMACEUTICALS INC | $0 | – | -901,115 | -100.0% | -1.96% | – |
| Exit | ABBVIE INCput | $0 | – | -50,000 | -100.0% | -2.18% | – | |
| MEDP | Exit | MEDPACE HLDGS INC | $0 | – | -116,053 | -100.0% | -2.39% | – |
| MDCO | Exit | MEDICINES COcall | $0 | – | -179,700 | -100.0% | -4.68% | – |
| ATHN | Exit | ATHENAHEALTH INCput | $0 | – | -57,600 | -100.0% | -5.01% | – |
| SNY | Exit | SANOFIsponsored adr | $0 | – | -223,380 | -100.0% | -5.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.